신경유전체학 검사 솔루션 시장 예측(-2034년) : 검사 유형별, 기술, 용도, 최종사용자, 지역별 세계 분석

According to Stratistics MRC, the Global Neurogenomics Testing Solutions Market is accounted for $1.8 billion in 2026 and is expected to reach $4.0 billion by 2034 growing at a CAGR of 10.4% during the forecast period. Neurogenomics testing solutions refer to specialized diagnostic platforms and sequencing methodologies designed to analyze the complete genetic and genomic architecture of the nervous system. They function by utilizing advanced molecular techniques to identify pathogenic variants, copy number variations, and epigenetic modifications associated with neurological and neurodevelopmental disorders. These solutions encompass whole genome sequencing, targeted gene panels, and chromosomal microarray analyses that enable precise molecular diagnosis, pharmacogenomic profiling, and personalized therapeutic interventions for complex brain-related conditions.

Market Dynamics:

Driver:

Rising Prevalence of Rare Neurological Disorders

The rising prevalence of rare neurological disorders compels providers to adopt neurogenomics testing solutions offering precise molecular diagnostic alternatives. Growing clinical recognition of genetic variants driving complex brain conditions accelerates the integration of sequencing platforms into standard care pathways. This transition is supported by advancements in sequencing throughput, which enhance diagnostic yield and reduce analysis timelines. Consequently, institutions are investing in genomic technologies to achieve accurate diagnoses while optimizing long-term patient management strategies.

Restraint:

High Costs and Reimbursement Limitations

The substantial expenses associated with comprehensive genomic sequencing and specialized bioinformatics analysis represent a significant barrier to widespread adoption. Developing accurate testing panels often requires complex molecular workflows and sophisticated data interpretation techniques, which escalate overall diagnostic costs. Furthermore, limited insurance reimbursement coverage for advanced neurogenomic assays restricts their operational accessibility for many patients. These factors collectively constrain market expansion, particularly for diagnostic laboratories operating with limited financial resources and tight operational budgets.

Opportunity:

Expansion in Pharmacogenomics and Targeted Therapies

The expanding pharmaceutical sector presents substantial growth opportunities for neurogenomics testing manufacturers due to increasing demand for pharmacogenomic profiling in targeted drug development. Genomic platforms offer a highly effective pathway to identify patient-specific genetic biomarkers without relying on traditional prescribing methods, utilizing sequencing data as primary inputs. As investments in precision medicine expand and regulators favor genetically guided therapeutic pathways, the adoption of advanced neurogenomic solutions is expected to surge, creating lucrative enterprise avenues.

Threat:

Data Privacy and Ethical Concerns

The innovation of alternative diagnostic methodologies and emerging point-of-care genetic devices poses a considerable threat to the neurogenomics testing market. Traditional rapid diagnostic assays and novel microfluidic platforms often exhibit superior turnaround times and can be more cost-effective for routine clinical applications. Additionally, the advancement of direct-to-consumer genetic testing enhances the accessibility of basic genomic information. This competitive pressure may hinder the penetration of specialized clinical neurogenomic solutions, particularly where cost and speed are primary considerations.

Covid-19 Impact:

The pandemic initially disrupted neurogenomics testing supply chains and delayed diagnostic research due to laboratory closures. However, the subsequent surge in demand for precise molecular diagnostics accelerated the adoption of advanced sequencing platforms for critical neurological assessments. Post-pandemic, the heightened focus on personalized medicine and genomic data integration has reinforced long-term investments in neurogenomics technologies, driving robust market recovery across diverse clinical sectors.

The whole genome sequencing (WGS) segment is expected to be the largest during the forecast period

The whole genome sequencing (WGS) segment is expected to account for the largest market share during the forecast period, due to its unparalleled comprehensive genomic coverage and widespread applicability across diverse clinical sectors. Whole genome sequencing offers exceptional diagnostic yield and operates effectively in identifying complex pathogenic variants, which significantly reduces diagnostic odysseys and minimizes unnecessary medical interventions. As healthcare systems increasingly prioritize precise molecular diagnostic methods, the demand for specialized WGS platforms continues to surge, thereby solidifying their dominant market position.

The next-generation sequencing (NGS) segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the next-generation sequencing (NGS) segment is predicted to witness the highest growth rate, driven by rapid advancements in high-throughput sequencing technologies and bioinformatics analytics. These technologies enable the precise analysis of multiple genetic targets to produce highly specialized and robust diagnostic outputs tailored for specific neurological applications. The ability to enhance sequencing speed, accuracy, and cost-efficiency through advanced NGS platforms significantly improves process economics. Consequently, increasing investments in genomic research and favorable clinical trends are accelerating commercial adoption.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share, due to the presence of well-established molecular diagnostics and genomic research industries that heavily utilize neurogenomics testing solutions. The region benefits from substantial research and development investments, robust intellectual property protection, and supportive government initiatives promoting precision medicine and genomic data integration. Furthermore, the early adoption of advanced sequencing technologies by key industry players in the United States and Canada reinforces the region's dominant position globally.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR, due to rapid healthcare modernization and expanding molecular diagnostics sectors in emerging economies. Countries such as China, India, and Japan are increasingly investing in genomic infrastructure and precision medicine technologies to meet growing domestic demand and rising awareness of rare neurological disorders. Additionally, favorable government policies, rising healthcare expenditures, and the availability of cost-effective sequencing platforms are collectively driving the accelerated adoption of neurogenomics testing solutions globally.

Key players in the market

Some of the key players in Neurogenomics Testing Solutions Market include Illumina, Inc., Thermo Fisher Scientific Inc., Invitae Corporation, Ambry Genetics (Konica Minolta), GeneDx (BioReference Laboratories), Fulgent Genetics, Inc., Blueprint Genetics, PreventionGenetics, Centogene N.V., Athena Diagnostics (Labcorp), Mayo Clinic Laboratories, ARUP Laboratories, Quest Diagnostics Incorporated, 23andMe, Inc., Color Genomics, Natera, Inc., and PerkinElmer, Inc.

Key Developments:

In September 2026, Illumina, Inc. launched a next-generation whole genome sequencing platform optimized for rare neurological disorders, achieving a thirty percent improvement in diagnostic yield while significantly reducing analysis time requirements for global clinical laboratories.

In August 2026, Thermo Fisher Scientific Inc. expanded its pharmacogenomics testing capacity in Europe through a strategic partnership with a leading research hospital, enabling the scalable deployment of novel targeted gene panels for personalized drug therapies.

In July 2026, Invitae Corporation secured a major supply agreement to provide customized chromosomal microarray analysis for a prominent pediatric network, facilitating the efficient integration of advanced diagnostic tools into next-generation neurodevelopmental assessment ecosystems globally.

Test Types Covered:

• Whole Genome Sequencing (WGS)
• Whole Exome Sequencing (WES)
• Targeted Gene Panels
• Pharmacogenomics Testing
• Chromosomal Microarray Analysis (CMA)
• Other Neurogenomic Tests

Technologies Covered:

• Next-Generation Sequencing (NGS)
• Polymerase Chain Reaction (PCR)
• Sanger Sequencing
• Microarray Technology
• Other Sequencing Technologies

Applications Covered:

• Rare Neurological Disorders
• Neurodegenerative Diseases
• Neurodevelopmental Disorders
• Psychiatric Disorders
• Neuromuscular Disorders
• Other Applications

End Users Covered:

• Hospitals and Clinics
• Diagnostic and Reference Laboratories
• Academic and Research Institutes
• Direct-to-Consumer (DTC) Genetic Testing Companies
• Pharmaceutical and Biotechnology Companies
• Other End Users

Regions Covered:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • United Kingdom
  • Germany
  • France
  • Italy
  • Spain
  • Netherlands
  • Belgium
  • Sweden
  • Switzerland
  • Poland
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Thailand
  • Malaysia
  • Singapore
  • Vietnam
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Colombia
  • Chile
  • Peru
  • Rest of South America
• Rest of the World (RoW)
  • Middle East
• Saudi Arabia
• United Arab Emirates
• Qatar
• Israel
• Rest of Middle East
  • Africa
• South Africa
• Egypt
• Morocco
• Rest of Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

• 1.1 Market Snapshot and Key Highlights
• 1.2 Growth Drivers, Challenges, and Opportunities
• 1.3 Competitive Landscape Overview
• 1.4 Strategic Insights and Recommendations

2 Research Framework

• 2.1 Study Objectives and Scope
• 2.2 Stakeholder Analysis
• 2.3 Research Assumptions and Limitations
• 2.4 Research Methodology
  • 2.4.1 Data Collection (Primary and Secondary)
  • 2.4.2 Data Modeling and Estimation Techniques
  • 2.4.3 Data Validation and Triangulation
  • 2.4.4 Analytical and Forecasting Approach

3 Market Dynamics and Trend Analysis

• 3.1 Market Definition and Structure
• 3.2 Key Market Drivers
• 3.3 Market Restraints and Challenges
• 3.4 Growth Opportunities and Investment Hotspots
• 3.5 Industry Threats and Risk Assessment
• 3.6 Technology and Innovation Landscape
• 3.7 Emerging and High-Growth Markets
• 3.8 Regulatory and Policy Environment
• 3.9 Impact of COVID-19 and Recovery Outlook

4 Competitive and Strategic Assessment

• 4.1 Porter's Five Forces Analysis
  • 4.1.1 Supplier Bargaining Power
  • 4.1.2 Buyer Bargaining Power
  • 4.1.3 Threat of Substitutes
  • 4.1.4 Threat of New Entrants
  • 4.1.5 Competitive Rivalry
• 4.2 Market Share Analysis of Key Players
• 4.3 Product Benchmarking and Performance Comparison

5 Global Neurogenomics Testing Solutions Market, By Test Type

• 5.1 Whole Genome Sequencing (WGS)
• 5.2 Whole Exome Sequencing (WES)
• 5.3 Targeted Gene Panels
• 5.4 Pharmacogenomics Testing
• 5.5 Chromosomal Microarray Analysis (CMA)
• 5.6 Other Neurogenomic Tests

6 Global Neurogenomics Testing Solutions Market, By Technology

• 6.1 Next-Generation Sequencing (NGS)
• 6.2 Polymerase Chain Reaction (PCR)
• 6.3 Sanger Sequencing
• 6.4 Microarray Technology
• 6.5 Other Sequencing Technologies

7 Global Neurogenomics Testing Solutions Market, By Application

• 7.1 Rare Neurological Disorders
• 7.2 Neurodegenerative Diseases
• 7.3 Neurodevelopmental Disorders
• 7.4 Psychiatric Disorders
• 7.5 Neuromuscular Disorders
• 7.6 Other Applications

8 Global Neurogenomics Testing Solutions Market, By End User

• 8.1 Hospitals and Clinics
• 8.2 Diagnostic and Reference Laboratories
• 8.3 Academic and Research Institutes
• 8.4 Direct-to-Consumer (DTC) Genetic Testing Companies
• 8.5 Pharmaceutical and Biotechnology Companies
• 8.6 Other End Users

9 Global Neurogenomics Testing Solutions Market, By Geography

• 9.1 North America
  • 9.1.1 United States
  • 9.1.2 Canada
  • 9.1.3 Mexico
• 9.2 Europe
  • 9.2.1 United Kingdom
  • 9.2.2 Germany
  • 9.2.3 France
  • 9.2.4 Italy
  • 9.2.5 Spain
  • 9.2.6 Netherlands
  • 9.2.7 Belgium
  • 9.2.8 Sweden
  • 9.2.9 Switzerland
  • 9.2.10 Poland
  • 9.2.11 Rest of Europe
• 9.3 Asia Pacific
  • 9.3.1 China
  • 9.3.2 Japan
  • 9.3.3 India
  • 9.3.4 South Korea
  • 9.3.5 Australia
  • 9.3.6 Indonesia
  • 9.3.7 Thailand
  • 9.3.8 Malaysia
  • 9.3.9 Singapore
  • 9.3.10 Vietnam
  • 9.3.11 Rest of Asia Pacific
• 9.4 South America
  • 9.4.1 Brazil
  • 9.4.2 Argentina
  • 9.4.3 Colombia
  • 9.4.4 Chile
  • 9.4.5 Peru
  • 9.4.6 Rest of South America
• 9.5 Rest of the World (RoW)
  • 9.5.1 Middle East
    • 9.5.1.1 Saudi Arabia
    • 9.5.1.2 United Arab Emirates
    • 9.5.1.3 Qatar
    • 9.5.1.4 Israel
    • 9.5.1.5 Rest of Middle East
  • 9.5.2 Africa
    • 9.5.2.1 South Africa
    • 9.5.2.2 Egypt
    • 9.5.2.3 Morocco
    • 9.5.2.4 Rest of Africa

10 Strategic Market Intelligence

• 10.1 Industry Value Network and Supply Chain Assessment
• 10.2 White-Space and Opportunity Mapping
• 10.3 Product Evolution and Market Life Cycle Analysis
• 10.4 Channel, Distributor, and Go-to-Market Assessment

11 Industry Developments and Strategic Initiatives

• 11.1 Mergers and Acquisitions
• 11.2 Partnerships, Alliances, and Joint Ventures
• 11.3 New Product Launches and Certifications
• 11.4 Capacity Expansion and Investments
• 11.5 Other Strategic Initiatives

12 Company Profiles

• 12.1 Illumina, Inc.
• 12.2 Thermo Fisher Scientific Inc.
• 12.3 Invitae Corporation
• 12.4 Ambry Genetics (Konica Minolta)
• 12.5 GeneDx (BioReference Laboratories)
• 12.6 Fulgent Genetics, Inc.
• 12.7 Blueprint Genetics
• 12.8 PreventionGenetics
• 12.9 Centogene N.V.
• 12.10 Athena Diagnostics (Labcorp)
• 12.11 Mayo Clinic Laboratories
• 12.12 ARUP Laboratories
• 12.13 Quest Diagnostics Incorporated
• 12.14 23andMe, Inc.
• 12.15 Color Genomics
• 12.16 Natera, Inc.
• 12.17 PerkinElmer, Inc.